Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study

Boswood, A; Gordon, S G; Häggström, J; Vanselow, M; Wess, G; Stepien, R L; Oyama, M A; Keene, B W; Bonagura, J; MacDonald, K A; Patteson, M; Smith, S; Fox, P R; Sanderson, K; Woolley, R; Szatmári, V; Menaut, P; Church, W M; O'Sullivan, M L; Jaudon, J-P; Kresken, J-G; Rush, J; Barrett, K A; Rosenthal, S L; Saunders, A B; Ljungvall, I; Deinert, M; Bomassi, E; Estrada, A H; Fernández-Del Palacio, M J; Moise, N S; Abbott, J A; Fujii, Y; Spier, A; Luethy, M W; Santilli, R A; Uechi, M; Tidholm, A; Schummer, C; Watson, P

doi:10.1111/jvim.15753

All Outputs (2)

Risk indictors in cats with preclinical hypertrophic cardiomyopathy: a prospective cohort study (2020)
Journal Article
Ironside, V. A., Tricklebank, P. R., & Boswood, A. (2020). Risk indictors in cats with preclinical hypertrophic cardiomyopathy: a prospective cohort study. Journal of Feline Medicine and Surgery, 1098612X2093865

Objectives
This study aimed to identify indicators of the risk of progression of preclinical hypertrophic cardiomyopathy (HCM).

Methods
This was a prospective cohort study following a population of cats with preclinical HCM. Cats serially underw... Read More about Risk indictors in cats with preclinical hypertrophic cardiomyopathy: a prospective cohort study.

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study (2020)
Journal Article
Boswood, A., Gordon, S. G., Häggström, J., Vanselow, M., Wess, G., Stepien, R. L., Oyama, M. A., Keene, B. W., Bonagura, J., MacDonald, K. A., Patteson, M., Smith, S., Fox, P. R., Sanderson, K., Woolley, R., Szatmári, V., Menaut, P., Church, W. M., O'Sullivan, M. L., Jaudon, J.-P., …Watson, P. (2020). Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study. Journal of Veterinary Internal Medicine, https://doi.org/10.1111/jvim.15753

The Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical myxomatous mitral valve disease (EPIC) study monitored dogs with myxomatous mitral valve disease (MMVD) as they developed congestive heart failure (CHF).